Product Description
Alefacept (Amevive®, Astellas Pharma US, Inc.) is a full dimeric human fusion protein, which consists of an extracellular portion of the human leukocyte function antigen-3 (LFA-3) fused to the Fc portion of immunoglobulin G1. Alefacept is the first biological agent approved by the US Food and Drug Administration (FDA) for the treatment of moderate to severe chronic plaque psoriasis. It is a full human fusion protein binding to CD2 on T cells. With its dual mechanism of action, alefacept blocks the interaction between the leukocyte-function-associated antigen (LFA)-3 and CD2 and thereby impedes the activation and proliferation of T cells. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2386357/)
Mechanisms of Action: LFA3 Inhibitor, CD2 Inhibitor
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: Intramuscular, Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Canada | Chile | Peru | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Astellas Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Crohn Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12617001426370p |
HSC20200410H | P1 |
Not yet recruiting |
Crohn Disease |
2018-04-17 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/01/2024 |
News Article |
LA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFE |
|
08/20/2024 |
News Article |
OTEZLA® (APREMILAST) NOW AVAILABLE IN THE U.S. FOR MODERATE TO SEVERE PEDIATRIC PLAQUE PSORIASIS |
|
09/28/2022 |
News Article |
Morphic Congratulates Timothy A. Springer, PhD as 2022 Albert Lasker Basic Medical Research Award Honoree |
|
09/08/2022 |
News Article |
AMGEN ANNOUNCES POSITIVE NEW DATA AT EADV 2022 FOR OTEZLA® (APREMILAST) |